<DOC>
	<DOCNO>NCT00134511</DOCNO>
	<brief_summary>The Torcetrapib project terminate December 2 , 2006 due safety finding . To evaluate efficacy safety lipid drug Torcetrapib/atorvastatin patient genetically know disorder extremely high cholesterol</brief_summary>
	<brief_title>Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder</brief_title>
	<detailed_description>For additional information please call : 1-800-718-1021</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<criteria>Diagnosis Homozygous Familial Hypercholesterolemia Women pregnant lactating , plan become pregnant . Subjects clinically indicate need statin ( HMGCoA reductase inhibitor ) therapy atorvastatin concomitant therapy know lipid alter effect LDLC HDLC include fibrates nicotinic acid Subjects take drug know associate increase risk myositis combination HMGCoA reductase inhibitor Subjects medical condition laboratory abnormality could affect subject safety , preclude evaluationof response , render unlikely subject would complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>